XENETIC BIOSCIENCES, INC. Fair Value Adjustment of Warrants
XENETIC BIOSCIENCES, INC. (XBIO) reported Fair Value Adjustment of Warrants of -$22.00 thousand for the 3-month period ending 2017-09-30, per its 10-Q filed 2017-11-14.
Discontinued › Cash Flow › Other Cash Flow Items
us-gaap:FairValueAdjustmentOfWarrants · last filed 2017-11-14
- XENETIC BIOSCIENCES, INC. fair value adjustment of warrants for the quarter ending 2017-09-30 was -$22.00K.
- XENETIC BIOSCIENCES, INC. fair value adjustment of warrants for the quarter ending 2017-06-30 was -$80.56K, a 105.89% decline year-over-year.
- XENETIC BIOSCIENCES, INC. fair value adjustment of warrants for the quarter ending 2017-03-31 was -$15.35K.
- XENETIC BIOSCIENCES, INC. fair value adjustment of warrants for the quarter ending 2016-12-31 was $21.47K, a 95.83% decline year-over-year.
- XENETIC BIOSCIENCES, INC. fair value adjustment of warrants for fiscal 2016 was $1.12M, a 20.17% increase from fiscal 2015.
- XENETIC BIOSCIENCES, INC. fair value adjustment of warrants for fiscal 2015 was $933.20K, a 289.01% increase from fiscal 2014.
- XENETIC BIOSCIENCES, INC. fair value adjustment of warrants for fiscal 2014 was $239.89K.
| Period end | Fair Value Adjustment of Warrants 3 month | Fair Value Adjustment of Warrants 3 month as first filed | Fair Value Adjustment of Warrants 6 month | Fair Value Adjustment of Warrants 9 month | Fair Value Adjustment of Warrants 9 month as first filed | Fair Value Adjustment of Warrants 12 month |
|---|---|---|---|---|---|---|
| 2017-09-30 | -$22.00K 10-Q · filed 2017-11-14 | -$102.56K derived: sum of 2 quarters · filed 2017-11-14 | -$100.00K 10-Q · filed 2017-11-14 | -$96.44K derived: sum of 4 quarters · filed 2017-11-14 | ||
| 2017-06-30 | -$80.56K derived: 10-Q 6 month − 10-Q 3 month · filed 2017-08-14 | -$95.91K 10-Q · filed 2017-08-14 | -$74.44K derived: sum of 3 quarters · filed 2017-08-14 | -$76.44K derived: sum of 4 quarters · filed 2017-11-14 | ||
| 2017-03-31 | -$15.35K 10-Q · filed 2017-05-15 | $6.12K derived: sum of 2 quarters · filed 2017-05-15 | $4.12K derived: sum of 3 quarters · filed 2017-11-14 | $1.37M derived: sum of 4 quarters · filed 2017-11-14 | ||
| 2016-12-31 | $21.47K derived: 10-K 12 month − 10-Q 9 month · filed 2017-03-31 | $19.47K derived: sum of 2 quarters · filed 2017-11-14 | $1.39M derived: sum of 3 quarters · filed 2017-11-14 | $1.12M 10-K · filed 2017-03-31 | ||
| 2016-09-30 | -$2.00K 10-Q · filed 2017-11-14 | -$1.79K 10-Q · filed 2016-11-14 | $1.37M derived: sum of 2 quarters · filed 2017-11-14 | $1.10M 10-Q · filed 2017-11-14 | $1.12M 10-Q · filed 2016-11-14 | $1.63M derived: sum of 4 quarters · filed 2017-11-14 |
| 2016-06-30 | $1.37M derived: 10-Q 6 month − 10-Q 3 month · filed 2017-08-14 | $1.12M 10-Q · filed 2017-08-14 | $1.63M derived: sum of 3 quarters · filed 2017-08-14 | $1.96M derived: sum of 4 quarters · filed 2017-08-14 | ||
| 2016-03-31 | -$249.22K 10-Q · filed 2017-05-15 | $265.15K derived: sum of 2 quarters · filed 2017-05-15 | $591.27K derived: sum of 3 quarters · filed 2017-05-15 | $683.98K derived: sum of 4 quarters · filed 2017-05-15 | ||
| 2015-12-31 | $514.37K derived: 10-K 12 month − 10-Q 9 month · filed 2017-03-31 | $840.49K derived: sum of 2 quarters · filed 2017-03-31 | $933.20K derived: sum of 3 quarters · filed 2017-03-31 | $933.20K 10-K · filed 2017-03-31 | ||
| 2015-09-30 | $326.12K 10-Q · filed 2016-11-14 | $418.83K derived: sum of 2 quarters · filed 2016-11-14 | $418.83K 10-Q · filed 2016-11-14 | |||
| 2015-06-30 | $92.70K derived: 10-Q 6 month − 10-Q 3 month · filed 2016-08-15 | $92.70K 10-Q · filed 2016-08-15 | ||||
| 2015-03-31 | $0.00 10-Q · filed 2016-05-16 | |||||
| 2014-12-31 | $239.89K 10-K · filed 2016-03-30 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| ProPhase Labs, Inc. (PRPH) | United States | $0.006B | -0.06 |
| Processa Pharmaceuticals, Inc. (PCSA) | United States | $0.005B | |
| AMARIN CORP PLC\UK (AMRN) | $0.005B | -247.24 | |
| Pulmatrix, Inc. (PULM) | United States | $0.006B | |
| Ernexa Therapeutics Inc. (ERNA) | United States | $0.006B | |
| Dermata Therapeutics, Inc. (DRMA) | United States | $0.005B | -0.62 |
| REVIVA PHARMACEUTICALS HOLDINGS, INC. (RVPH) | United States | $0.005B | |
| Cadrenal Therapeutics, Inc. (CVKD) | United States | $0.004B | -0.90 |
| Lakewood-Amedex Biotherapeutics Inc. (LABT) | United States | $0.004B | |
| Enveric Biosciences, Inc. (ENVB) | United States | $0.007B | -0.63 |